 |
|
| Blog results | Results 1 - 10 of about 4,881 for raloxifene research. (0.36 seconds) |
| Sorted by relevance Sort by date |
| 16 Nov 2009 by David Gorski Indeed, raloxifene, another SERM, is used primarily to prevent and treat bone loss in women with osteoporosis. A $110 million clinical trial showed that its ability to prevent breast cancer is not statistically significantly different ... Science-Based Medicine - http://www.sciencebasedmedicine.org/ - References |
| 10 Nov 2009 by NHS Choices This research gave an osteoporosis drug called raloxifene, a cancer drug called fulvestrant or no treatment to mice that were genetically engineered to develop cervical cancer when treated with oestrogen. The drugs reduced the incidence ... Health News from NHS Choices - http://www.nhs.uk/News/Pages/NewsArticles.aspx - References |
| 29 Oct 2009 by Legault, Maki, Resnick, Coker, Hogan, Bevers,... NO1-AG-2106 and in part by the Intramural Research Program, National Institute on Aging, National Institutes of Health (Co-STAR); supported by Public Health Service Grants No. U10-CA-37377, U10-CA-69974, U10CA-12027, and U10CA-69651 ... Journal of Clinical Oncology Current Issue - http://jco.ascopubs.org/ [ More results from Journal of Clinical Oncology Current Issue ] |
| 18 Nov 2009 by Dr.Shruti Bhat Tamoxifen was also more likely than a placebo to lead to endometrial cancer and more likely to cause cataracts than was raloxifene. Disclaimer : The above information has been cited from literature in public domain. This is for research ... Pharmacy Education And Research .Com - http://www.pharm-education.com/ |
| 2 Nov 2009 by Kondo, M., Hoshi, S.-L., Toi, M. Budget Impact Analysis of Chemoprevention of Breast Cancer with Tamoxifen and Raloxifene among High-risk Women in Japan. Masahide Kondo1,2, Shu-Ling Hoshi1 and Masakazu Toi3. 1 Department of Health Care Policy and Management, Graduate School of ... 2 Clinical Research Division, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Bunkyo-ku, Tokyo 3 Department of Surgery, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, Japan ... Japanese Journal of Clinical Oncology -... - http://jjco.oxfordjournals.org/ |
| 17 Nov 2009 A systematic review carried out on behalf of the US Agency for Healthcare Research and Quality (AHRQ) concludes that tamoxifen, raloxifene, and tibolone can reduce the risk of primary breast cancer, however all are also associated with ... NeLM - News - http://www.nelm.nhs.uk/en/NeLM-Area/News/ [ More results from NeLM - News ] |
| 19 Nov 2009 by Nelson HD, Fu R, Griffin JC, Nygren P,... ... reduce risk for primary breast cancer but increase risk for thromboembolic events (tamoxifen, raloxifene), endometrial cancer (tamoxifen), or stroke (tibolone). Primary Funding Source: Agency for Healthcare Research and Quality. ... JournalFeeds - http://journalfeeds.com/ |
| 3 Oct 2009 by admin Not clearly, why the protection given raloxifene, is the biggest among those who is genetically predisposed to a mammary gland cancer, but clearly results are encouraging for these women. Research in raloxifene and as it is compared ... Blog about effective pharmacy - http://myraspberry.com/blog/ |
| 20 Nov 2009 by admin A recent report from the Department of Health and Human Services' Agency for Healthcare Research and Quality reported that although three drugs (tamoxifen, raloxifene, and tibolone) reduce a woman's chances of getting breast cancer each ... Holistic Health Show - http://www.holistichealthshow.com/wordpress/ |
| 25 Nov 2009 by Mike Stobbe Issued by HHS' Agency for Healthcare Research and Quality, the report reveals that the three drugs are tamoxifen, raloxifene, and tibolone. CDC chief says swine flu vaccine will be safe, his kids to get it when it becomes available ... Health News - http://blog.taragana.com/health/ - References [ More results from Health News ] |
Stay up to date on these results:
| Google Home - About Google Blog Search Beta - Information for Blog Authors |
